U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07470606) titled 'Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain' on March 09.
Brief Summary: The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues.
The study will include anyone over the age of 18 who will be treated with radiation for brain cancer.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Brain Tumor
Intervention:
DRUG: Memantine
The goal dose for Immediate Release Memantine is 10 mg oral twice daily. The goal-dose for Extended-Release Memantine is 2...